AR
SANA icon

Advisory Research’s Sana Biotechnology SANA Stock Holding History

Advisory Research’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40,179
Closed -$164K – 289
2023
Q4 		$164K Buy
+40,179
New +$148K 0.03% 325
2023
Q3 		– Sell
-19,806
Closed -$118K – 476
2023
Q2 		$118K Buy
+19,806
New +$114K 0.02% 433

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Advisory Research's SANA Position: Q1 2024 in Review

Advisory Research sold out of Sana Biotechnology (SANA) in Q1 2024, closing a stake of 40,179 shares — an estimated $164K sold.

Advisory Research first reported a position in SANA in Q2 2023 and held it in 2 quarters. The position peaked at $164K in Q4 2023. 154 funds tracked by Wall St. Rank hold SANA as of Q1 2024.

  • Advisory Research reported no remaining Sana Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 40,179 Sana Biotechnology shares in Q1 2024, an estimated $164K.
  • Advisory Research first reported a position in Sana Biotechnology in Q2 2023 and held it in 2 quarters.
  • Advisory Research's Sana Biotechnology position peaked at $164K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.